Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$59.56−1.79 (-2.92%)
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
Bristol Myers Squibb revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bristol Myers Squibb's revenue for the twelve months ending Sep 30, 2026 was $50.03B, up 4.2% year over year. For fiscal 2025 it was $48.19B, down 0.2% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $48.30B in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.19B | -0.2% |
| FY2024 | Dec 31, 2024 | $48.30B | +7.3% |
| FY2023 | Dec 31, 2023 | $45.01B | -2.5% |
| FY2022 | Dec 31, 2022 | $46.16B | -0.5% |
| FY2021 | Dec 31, 2021 | $46.39B | +9.1% |
| FY2020 | Dec 31, 2020 | $42.52B | +62.6% |
| FY2019 | Dec 31, 2019 | $26.15B | +15.9% |
| FY2018 | Dec 31, 2018 | $22.56B | +8.6% |
| FY2017 | Dec 31, 2017 | $20.78B | +6.9% |
| FY2016 | Dec 31, 2016 | $19.43B | +17.3% |
| FY2015 | Dec 31, 2015 | $16.56B | +4.3% |
| FY2014 | Dec 31, 2014 | $15.88B | -3.1% |
| FY2013 | Dec 31, 2013 | $16.39B | -7.0% |
| FY2012 | Dec 31, 2012 | $17.62B | -17.1% |
| FY2011 | Dec 31, 2011 | $21.24B | +9.0% |
| FY2010 | Dec 31, 2010 | $19.48B | +3.6% |
| FY2009 | Dec 31, 2009 | $18.81B | +6.2% |
| FY2008 | Dec 31, 2008 | $17.72B | +13.4% |
| FY2007 | Dec 31, 2007 | $15.62B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.07B | +6.9% |
| Q2 FY2026 | Jun 30, 2026 | $12.97B | +5.7% |
| Q1 FY2026 | Mar 31, 2026 | $11.49B | +2.6% |
| Q4 FY2025 | Dec 31, 2025 | $12.50B | +1.3% |
| Q3 FY2025 | Sep 30, 2025 | $12.22B | +2.8% |
| Q2 FY2025 | Jun 30, 2025 | $12.27B | +0.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.20B | -5.6% |
| Q4 FY2024 | Dec 31, 2024 | $12.34B | +7.5% |
| Q3 FY2024 | Sep 30, 2024 | $11.89B | +8.4% |
| Q2 FY2024 | Jun 30, 2024 | $12.20B | +8.7% |
| Q1 FY2024 | Mar 31, 2024 | $11.87B | +4.7% |
| Q4 FY2023 | Dec 31, 2023 | $11.48B | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $10.97B | -2.2% |
| Q2 FY2023 | Jun 30, 2023 | $11.23B | -5.6% |
| Q1 FY2023 | Mar 31, 2023 | $11.34B | -2.7% |
| Q4 FY2022 | Dec 31, 2022 | $11.41B | -4.8% |
| Q3 FY2022 | Sep 30, 2022 | $11.22B | -3.5% |
| Q2 FY2022 | Jun 30, 2022 | $11.89B | +1.6% |
| Q1 FY2022 | Mar 31, 2022 | $11.65B | +5.2% |
| Q4 FY2021 | Dec 31, 2021 | $11.99B | +8.3% |
| Q3 FY2021 | Sep 30, 2021 | $11.62B | +10.3% |
| Q2 FY2021 | Jun 30, 2021 | $11.70B | +15.5% |
| Q1 FY2021 | Mar 31, 2021 | $11.07B | +2.7% |
| Q4 FY2020 | Dec 31, 2020 | $11.07B | +39.3% |
| Q3 FY2020 | Sep 30, 2020 | $10.54B | +75.5% |
| Q2 FY2020 | Jun 30, 2020 | $10.13B | +61.5% |
| Q1 FY2020 | Mar 31, 2020 | $10.78B | +82.1% |
| Q4 FY2019 | Dec 31, 2019 | $7.95B | +33.0% |
| Q3 FY2019 | Sep 30, 2019 | $6.01B | +5.6% |
| Q2 FY2019 | Jun 30, 2019 | $6.27B | +10.0% |
| Q1 FY2019 | Mar 31, 2019 | $5.92B | +14.0% |
| Q4 FY2018 | Dec 31, 2018 | $5.97B | +9.6% |
| Q3 FY2018 | Sep 30, 2018 | $5.69B | +8.3% |
| Q2 FY2018 | Jun 30, 2018 | $5.70B | +10.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.19B | +5.4% |
| Q4 FY2017 | Dec 31, 2017 | $5.45B | +3.9% |
| Q3 FY2017 | Sep 30, 2017 | $5.25B | – |
| Q2 FY2017 | Jun 30, 2017 | $5.14B | – |
| Q1 FY2017 | Mar 31, 2017 | $4.93B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.24B | – |
See a number that looks wrong?